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Abstract
Homologous recombination in Saccharomyces cerevisiae is a well-studied process. Here, we describe a yeast-recombination-
based approach to construct and mutate plasmids containing the cDNA of the human bile salt export pump (BSEP) that has
been shown to be unstable in E. coli. Using this approach, we constructed the necessary plasmids for a heterologous
overexpression of BSEP in the yeast Pichia pastoris. We then applied a new site-directed mutagenesis method, DREAM
(Directed REcombination-Assisted Mutagenesis) that completely bypasses E. coli by using S. cerevisiae as the plasmid host
with high mutagenesis efficiency. Finally, we show how to apply this strategy to unstable non-yeast plasmids by rapidly
turning an existing mammalian BSEP expression construct into a S. cerevisiae-compatible plasmid and analyzing the impact
of a BSEP mutation in several mammalian cell lines.
Citation: Stindt J, Ellinger P, Stross C, Keitel V, Ha ¨ussinger D, et al. (2011) Heterologous Overexpression and Mutagenesis of the Human Bile Salt Export Pump
(ABCB11) Using DREAM (Directed REcombination-Assisted Mutagenesis). PLoS ONE 6(5): e20562. doi:10.1371/journal.pone.0020562
Editor: Hendrik W. van Veen, University of Cambridge, United Kingdom
Received March 18, 2011; Accepted May 3, 2011; Published May 31, 2011
Copyright:  2011 Stindt et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the SFB 575 ‘‘Experimental hepatology’’ (project A9 to L.S.) and the KFO 217 ‘‘Hepatobiliary transport and liver diseases’’
(project TP1 to R.K. and TP3 to L.S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: lutz.schmitt@hhu.de
. These authors contributed equally to this work.
Introduction
Recombinant protein expression is a frequent necessity for
biochemical studies of proteins, which cannot be obtained in high
amounts from their natural source. Among these are many
membrane proteins. Extensive expression screening is a vital
initial step in the study of membrane proteins, and this stage
involves substantial work with recombinant DNA to create the
necessary expression constructs. Standard techniques of molec-
ular biology, however, become limiting when working with gene
sequences that are unstable in Escherichia coli. This is especially
encountered in the case of mammalian membrane proteins
[1,2,3]. Comprehensive studies that address the actual cloning,
propagation, and manipulation of constructs containing these
unstable DNA sequences are rare and often lack detailed
descriptions of the difficulties and, more importantly, of the
solutions. In the case of the human bile salt export pump (BSEP,
ABCB11), the cloning of the cDNA into an expression vector only
succeeded after a tremendous amount of work [2]. This process
resulted in a plasmid with several point mutations in the coding
sequence, six of which changed the sequence on the protein level.
A general issue encountered during propagation and targeted
mutagenesis of BSEP-containing plasmids is the loss of various
parts of the BSEP cDNA sequence in E. coli [2]. This loss of
sequences has been observed for other proteins as well [4]. The
corresponding DNA sequences have generally been termed
‘‘unstable’’ or even ‘‘toxic’’, because the presence of the intact
plasmid ultimately resulted in bacterial cell death.
One approach to create plasmids containing these ‘‘toxic’’
DNA fragments is to assemble it by homologous recombination
in Saccharomyces cerevisiae (S. cerevisiae) thereby circumventing E. coli
[5,6,7]. S. cerevisiae is able to recombine several overlapping
fragments into one circular plasmid containing the desired
cDNA. By incorporation of a suitable origin of replication (Ori)
as well as a selection marker virtually any plasmid can be created
for usage of recombination-based cloning by S. cerevisiae.A
fragment containing both ORI and selection marker can be
added together with the toxic target cDNA in a single
recombination step yielding an intact and most importantly
stable expression plasmid.
We have used S. cerevisiae to create such an expression plasmid
containing the ‘‘toxic’’ coding sequence of human BSEP which
was subsequently used for BSEP expression in S. cerevisiae and
Pichia pastoris (P. pastoris). Severe hereditary diseases of the liver are
directly associated with mutations in the BSEP transporter [8,9].
Previously heterologous BSEP expression was only demonstrated
in insect cells [2], which hampered a detailed analysis of function
of both wild-type BSEP and clinically relevant mutations in vitro.
Besides creating an expression plasmid for BSEP in P. pastoris the
method described here is also used to directly create BSEP
mutants in the yeast plasmid for subsequent expression in
mammalian cell lines. This highlights the applicability of this
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well as more sophisticated expression in mammalian cell lines.
Results
Cloning and expression of BSEP
The unicelluar eukaryote S. cerevisiae was initially chosen because
of three advantages: (i) it can perform efficient homologous
recombination [5,7]; (ii) expression of other eukaryotic ABC
transporters has been successfully reported [10]. For example, S.
cerevisiae has been used to express the BSEP homologue MDR1
[11,12]. (iii) Transformants resulting from in vivo homologous
recombination can immediately be tested for target protein
expression. We used these advantages for BSEP, but expression
levels in S. cerevisiae were very low and not sufficient for subsequent
purification or activity studies (Figure 1B, left panel).
Therefore, we changed the expression system from S. cerevisiae to
P. pastoris. Here, expression is driven from the strong inducible
AOX1 promoter. In addition, this yeast strain can reach high cell
densities and thereby lead to substantial amounts of membrane
protein [13,14,15]. Furthermore, Chloupkova et al. were able to
express 25 human ABC transporters in P. pastoris [15], however
BSEP was not among them. We used the P. pastoris integration
vector pPIC3.5, which was prepared for manipulation in S.
cerevisiae by integrating the relevant sequence that is necessary for
maintenance (ORI) and selection in this yeast. A PCR product
containing the S. cerevisiae 2 micron ORI and a leucine
prototrophy marker and a second PCR product containing BSEP
with an C-terminal his8 tag (kind gift of Dr. Kenneth Linton) were
simultaneously recombined into pPIC3.5 in vivo in S. cerevisiae
(Figure 1A). The resulting derivative pPIC3.5-ChisBSEP (Figure
S1) is identical to the construct that would be obtained by
Figure 1. Heterologous overexpression of BSEP in Saccharomyces cerevisiae and Pichia pastoris.A ,Toxic or unstable expression plasmids
can be constructed for any system in S. cerevisiae by adding the necessary sequence to the plasmid backbone. In order to clone BSEP into the Pichia
pastoris expression cassette on pPIC3.5, the recombination vector was double-digested to allow the simultaneous insertion of both the unstable BSEP
coding sequence and a PCR-generated fragment of the YEpHIS plasmid carrying the 2 micron origin (Ori) of replication and the leucine (LEU)
prototrophy marker by homologous recombination (RS=NdeI). This plasmid was recovered from S. cerevisiae and obtained in preparative amounts
from E. coli by strict cultivation at 30uC under suitable conditions. B, Expression of human BSEP in S. cerevisiae and P. pastoris. Equal amounts of whole
yeast cell extracts were resolved on SDS-PAGE, electroblotted and probed with the polyclonal BSEP antiserum K168. Left panel, Homologous
recombination was used to construct both BSEP expression vectors directly in S. cerevisiae. NHIS/CHIS, N- or C-terminal his tag position; empty Ctrl,
strain transformed with corresponding empty YEpHIS expression plasmid. Right panel, pPIC3.5-CHISBSEP was constructed as described in A and
used to transform P. pastoris strain GS-115 by electroporation. Empty Ctrl, P. pastoris GS-115 strain transformed with the empty pPIC3.5 integration
vector.
doi:10.1371/journal.pone.0020562.g001
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introduced ORI and selection marker. The plasmid was used to
transform P. pastoris. Abundant colonies were obtained and twelve
of these were subsequently analyzed for BSEP expression. As
demonstrated by Western blot analysis, all of the tested clones
expressed BSEP at similar levels (Figure 1B, right panel). A strain
transformed with the empty integration vector was used as a
negative control. The yield of recombinant BSEP achieved in P.
pastoris is substantially higher than in S. cerevisiae allowing further
purification and subsequent biochemical analysis.
DREAM - A site-directed mutagenesis method for
unstable and toxic plasmids
Several severe hereditary diseases are known to be associated
with human ABC transporter genes [16]. To date, 146 BSEP
mutations have been reported in the Human Gene Mutation
Database [17], The vast majority of which are associated with liver
diseases. One of the most frequently used methods to generate
specific mutations is the site-directed mutagenesis (SDM) proce-
dure [18]. This method relies on the usage of E. coli to turn the
linear product obtained by an in vitro mutagenesis into a circular
plasmid via nick repair. However, since the cDNA BSEP is toxic
for E.coli, this standard method is not applicable. Therefore, we
used S. cerevisiae as host.
Classic SDM relies on the removal of non-mutated template
plasmid achieved by DpnI digestion, which recognizes and cleaves
only methylated DNA template. Thereby only the mutated
plasmid can give colonies. Plasmids prepared directly from S.
cerevisiae, however are, unmethylated and the template plasmid
cannot be removed by DpnI digestion [19,20,21]. Thereby, the
efficiency of mutagenesis is too low. To obtain positive clones,
several hundred nanograms of mutated plasmid are needed and a
substantial amount of time is required to pick and analyze several
clones to find the correctly mutated plasmid [22,23,24]. By
changing the mutagenesis primer design from a complete to a
partial, 59-overlap of the primer pair (Figure 2A, step 1), the linear
in vitro mutagenesis step is turned into an exponential polymerase
chain reaction: due to this primer shift a product is generated
which carries priming sites that serve as a template in the
subsequent reaction cycles (step 2). The usefulness of such a primer
shift was previously reported, although in a different context [25].
The reaction product is therefore endowed with homologous
double-stranded ends that allow the precise recirculation by
homologous recombination into an intact plasmid (step 3; for a
detailed comparison of both, classic and DREAM mutagenesis, see
Figure S2). A change of primers to mutated plasmid DNA used for
transformation thereby increases the probability of picking positive
mutated clones.
We analyzed the efficiency of this yeast-based mutagenesis
method by introducing a mutation into BSEP on a S. cerevisiae
plasmid that resulted in an additional recognition site for the
restriction enzyme BstBI (Figure 2B). The mutagenesis reaction
gave ,100 colonies after transformation. Twenty-five of the
resulting transformants were picked and the mutated region of the
plasmid was amplified by colony PCR. The product of 1240 bp
was then subjected to BstBI digestion, which - assuming that the
site directed mutagenesis has been successful - should result in two
bands of 960 and 280 bp, respectively. Since no BstB1 site was
present in the amplified DNA, the PCR product of colonies not
bearing the mutation cannot be digested by this restriction
enzyme. From 25 clones picked, 19 carried the introduced
mutation, corresponding to a mutagenesis efficiency of 76%. Five
of these mutated plasmids where sequenced and all of them were
positive for the mutation. The efficiency of two other mutations
generated by this strategy was 74%. This demonstrates that our
method is comparable to the 80% efficiency reported for the E.
coli-dependent, classical SDM [26].
Rapid DREAM mutagenesis and expression analysis of a
yeast-enabled mammalian BSEP expression vector
Many eukaryotic membrane proteins are expressed and studied
in mammalian cell lines [27,28]. In order to extend the usage of
the DREAM method to human cell culture, a yeast-compatible
derivative of the mammalian BSEP expression vector pEYFP-N1-
BSEP [29] (Figure S1) was created by introducing the necessary S.
cerevisiae ORI and selection marker(in analogy to the P. pastoris
vector modification shown in Figure 1A). After introduction and
sequence verification, the obtained plasmid construct was
successfully transfected into HEK293 cells as visualized by
detection of the fluorescent YFP tag at the C-terminus of the
BSEP fusion protein (Figure 3). Comparison with the parental
non-yeast expression vector showed that in both cases BSEP is
localized at the plasma membrane (Figure 3A and B). Additionally,
flow cytometric analyses of HEK293 cells transfected with
equimolar amounts of BSEP in pEYFP-N1 and in pEYFP-N1-
OriLeu, respectively, were performed to determine transfection
and expression rates of both plasmids (Figure S3). Here,
transfection rates and BSEP expression from the larger yeast
shuttle vector and the smaller, parental vector were found to be
comparable (21% and 32%, respectively). These experiments,
show that the presence of the additional ORI and selection marker
does not influence the expression of BSEP in mammalian cell
cultures.
We introduced a BstBI mutation by the E. coli-free DREAM
method as described above. After plasmid recovery, expression
was analyzed by transfection in different mammalian cell lines
(Figure 3C). The green fluorescence of the BSEP mutant fusion
protein could be detected in HEK293, MDCK and HepG2 cells.
Here, a mislocalization of the mutated ABC transporter from the
plasma membrane to intracellular compartments could be
observed (Figure 3C). This mislocalization has also been observed
in a liver biopsy from a patient carrying this BSEP mutation
(Kubitz and Ha ¨ussinger, unpublished data).
Discussion
Here we present a complete, yeast-based workflow to create and
manipulate unstable or toxic genes for any expression system. By
using this method, we were able to express the ‘‘toxic’’ human
wild-type BSEP cDNA both in S. cerevisiae and P. pastoris.
Furthermore it is possible to rapidly generate and study BSEP
mutations and to use the resultant plasmids in yeast and
mammalian expression systems without further modifications.
We describe and provide proof of principle for DREAM, a new
site-directed mutagenesis method that allows the site-specific
manipulation of plasmids in S. cerevisiae. This method can be used
for many plasmids by simple addition of the sequence necessary
for S. cerevisiae plasmid maintenance. Moreover, these plasmids can
also be obtained in sufficient quantity and quality directly from S.
cerevisiae cultures [30]. The presented approach can rely on S.
cerevisiae as the single organism used in all cloning steps from
plasmid construction and propagation as well as its mutagenesis.
Homologous recombination has other additional advantages:
since the recombination process is completely independent of
restriction sites, the in-frame fusion of an insert to e.g. a plasmid-
encoded tag never results in unwanted additional amino acids on
the recombinant protein, while this is often the case in restriction-
or LIC-based cloning [31,32] (ligation-independent cloning). At
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throughput-compatible as LIC.
DREAM - Directed REcombination-Assisted Mutagenesis
The modified primer design of the yeast-based DREAM
mutagenesis method is simple and like the classic SDM covers
all aspects of mutagenesis: mutation, insertion and deletion (see
Figure S2). The DREAM mutagenesis primer pair can easily be
designed by the following basic rules: each oligonucleotide
should be around 50 bases long, with 20 bases of 59 primer-to-
primer overlap for an efficient recombination of the mutated
plasmid ends in yeast, carrying the mutation, deletion or
insertion in their middle, and 30 bases of 39-sequence for
template annealing. The 20 bp overlap on both ends of the
linear mutagenesis product results in efficient homology-based
gap repair in S. cerevisiae to form the circular, mutated plasmid
(Figure 2). To minimize the occurrence of errors, the number of
thermal cycles is restricted to 18 as recommended for the
conventional SDM kit [26]. Accordingly, all analyzed DREAM
clones so far replicated the template plasmid sequence i.e. apart
from the introduced mutation the whole BSEP coding sequence
was found to be unchanged.
The new mutagenesis method permits the rapid realization of
patient-derived BSEP mutations for immediate study in cell
cultures. Using DREAM, we could show that a BSEP mutation
identified in a patient with progressive familial intrahepatic
cholestasis type 2 results in a trafficking defect of the mutant
protein that prevents BSEP from being correctly incorporated into
the plasma membrane. Future mutations can be generated quickly
for their study in mammalian cell lines and/or in vitro on the
isolated recombinant protein. This is a major advantage since the
realization of for example BSEP mutations was previously a work-
intensive and time-consuming task. Glycosylation has been shown
to be irrelevant for the function of other human ABC transporters
expressed in yeast in the past [12,33]. Furthermore, BSEP
expressed in Sf9 cells, which also harbors a glycosylation pattern
different from the human pattern, was functional [2]. Thus, it is
very likely that the glycosylation state and/or pattern of BSEP is
not relevant for its function.
Concluding remarks
We have established and validated a complete new workflow for
the cloning and manipulation of ‘‘unstable or toxic’’ DNA. We
believe that in particular the new E. coli-independent DREAM
mutagenesis strategy will be helpful for proteins where functionally
relevant mutants of proteins could not be studied due to limitations
of their bacterial cloning.
Materials and Methods
Yeast strains and growth conditions
The Saccharomyces cerevisiae strain used in this study was the
S288C derivative YRE1001 (MATa; ura3–52; trp1-1; leu2–3,112;
his3–11, 15; ade2-1; pdr1–3;DPDR5,DPDR5prom::TRP1) [34]. For
expression in Pichia pastoris, strain GS-115 from Invitrogen was
used. Yeast cells were maintained either on YPD agar (1% (w/v)
yeast extract, 2% (w/v) peptone from caseine, 2% (w/v) glucose,
and 2% (w/v) agar for solid media) or synthetic complete (SC)
minus leucine media [35] at 30uC, and liquid cultures were shaken
at 200 (S. cerevisiae) or 250 rpm (P. pastoris), respectively.
Figure 2. The DREAM method allows site-directed mutagenesis of an unstable BSEP-carrying plasmid without the need for E. coli.A ,
The product yield can be increased significantly by shifting the primer binding sites from a complete to a partial overlap that allows binding of the
primers to product in subsequent cycles. The minute amount (10 ng) of non-mutated template used in the reaction is easily outnumbered by the
yield of mutagenesis product, which is double-stranded (ds) due to the modified primer design (see also Figure S2). This allows for the direct
transformation of S. cerevisiae without the need of prior template removal. The mutagenesis product is then recircularized by homologous
recombination of the double-stranded ends. B, Analysis of S. cerevisisae transformants obtained from the modified SDM protocol shows a high
mutagenesis efficiency. Successful mutagenesis in this case results in the addition of an BstBI restriction site into the BSEP coding sequence. Colony
PCR of the resulting transformants was performed with primers surrounding the mutagenesis site, and the resulting product was digested with BstBI.
19 of the 25 tested clones carried the additional restriction site (+), corresponding to a mutagenesis efficiency of 76%.
doi:10.1371/journal.pone.0020562.g002
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All polymerase-based reactions were performed with the
Phusion H High Fidelity DNA polymerase (NEB) and the supplied
HF buffer. Restriction enzymes were from NEB and Fermentas.
Oligonucleotides were ordered from Eurofins MWG Operon
(Ebersberg, Germany). Plasmid miniprep kits were obtained from
Qiagen (Hilden, Germany), and the Nucleobond H Xtra midiprep
kit from Macherey-Nagel was used (Du ¨ren, Germany).
Generation of PCR products and preparation of vectors
for homologous recombination in S. cerevisiae
The Clone Manager Suite 6 (Sci-Ed Software) was used to
design all oligonucleotides and calculate annealing temperatures
of the primer pairs. All oligonucleotides and plasmids used in this
study can be found in Table S1 and S2, respectively. All PCR
reactions were performed with the PhusionH DNA polymerase in
HF buffer according to the recommendations of the manufac-
turer. 50 ml reactions contained 1.5 ml of DMSO. PCR
conditions were: 2 min initial denaturation, 50 sec cycle dena-
turation, 50 sec annealing, 20 sec per kbp of extension for 35
cycles, followed by 7 min of final extension. For homologous
recombination, all vectors were linearized by restriction digest as
indicated during which they also were dephosporylated with calf
intestinal alkaline phosphatase (Fermentas). YEpMDR1HIS was
double-digested with BamHI and BsmI, YEpHIS was cut with
BamHI and MluI to remove the C-terminal his tag [12]. The
oligonucleotides YEpNHISFor and YEpNHISRev encoding an
N-terminal his14 tag followed by a factor Xa cleavage site were
mixed in equimolar amounts, heated to 95uC for 5 min and
allowed to anneal by slow cooling to room temperature. After T4
polynucleotide kinase (NEB) treatment, the phosphorylated
synthetic insert was ligated into the gel-purified linearized
YEpHIS plasmid. BSEP PCR products with fitting overlaps were
generated with the primer pairs BSEP-YEpHISN-S1/-S2 and
BSEP-YEpHISC-S1/-S2, respectively.
Transformation of competent S. cerevisiae cells
Competent cells were generated as described elsewhere [24].
Briefly, a 5 ml overnight culture was used to inoculate 50 ml YPD
to an OD600 of 0.2. Cells were harvested at an OD600 of 0.8 to 1
and washed once with 50 ml of sterile water. The cell pellet was
then washed once in 1 ml of LATE buffer (0.1 M lithium acetate,
10 mM Tris-HCl pH 8, 1 mM EDTA) and adjusted to 50 ml
LATE per 10 OD600 equivalents of cells. Cells were directly used
or stored for a maximum of two days at 4uC. Competent yeast
cells were transformed either with intact plasmid or equimolar
amounts of DNA fragments for homologous recombination using
the Lithium-Acetate/PEG method [24] without single-stranded
DNA, and transformants were selected on solid SC minus leucine
media. The DNA for yeast transformation was salt/ethanol-
precipitated, briefly dried and directly redissolved in the yeast
suspension. Resulting transformants were directly used to
Figure 3. The yeast-maintainable BSEP expression plasmid is functionally indistinguishable from the non-yeast parental plasmid in
mammalian cell culture. A, HEK293 cells were transfected with pEYFP-N1-BSEP. B, HEK293 cells were transfected with pEYFP-N1-OriLeu-BSEP.
Equimolar amounts of both constructs showed comparable transfection efficiencies and expression levels (established by FACS analysis, see Figure
S3). C, HEK293 (upper panel), MDCK (middle), and HepG2 cells (lower panel) were transfected with the BstBI mutation in pEYFP-N1-OriLeu-BSEP that
was introduced with the E. coli-free site-directed mutagenesis method. All cells were transfected with equimolar amounts of the respective constructs
via Lipofectamine according to the manufacturer’s guidelines. After fixation, nuclei were stained with Hoechst 34580 (blue), and the fluorescence
(green) of the YFP tag in the BSEP fusion protein was observed.
doi:10.1371/journal.pone.0020562.g003
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inoculated to an OD600 of 0.3 and harvested in the early
logarithmic growth stage (OD600 of 1).
Analysis of BSEP expression in Pichia pastoris
The primer pair OriLeu-pPIC3.5-NdeI-S1/-S2 was used to
amplify the region of the YEpHIS plasmid containing the
2 micron ori and the leucine prototrophy marker (the sequence
of YEpLac181, the parental vector of YEpHIS1 containing the ori
and marker information can be found under Genbank acc.
no. X75460.1), and BSEP was amplified with primers BSEP-
pPIC3.5-S1/-S2. pPIC3.5 was double-digested with NdeI and
BamHI, and all fragments were pooled in equimolar amounts and
used for transformation of S. cerevisiae. After plasmid recovery in E.
coli XL1blue, the Pichia pastoris strain GS-115 was transformed
according to the Invitrogen guidelines. Clones obtained from
transformation were subjected to a second round of selection on
MD plates without histidine. From these, 10 ml MGY cultures
were grown overnight at 30uC and 250 rpm shaking. Cells were
pelleted at an OD600 between 2 to 6 (1500 g, 5 min, 4uC) and
resuspended in MMY medium to a final OD600 of 1. After
additional growth for 24 h, 10 OD600 equivalents were harvested
and used to make whole cell lysates. Cells were washed once with
water, resuspended in 1 ml of water, and lysed on ice for 10 min by
addition of 150 ml of YEX buffer (1.5 M NaOH, 7.5% (v/v) b-
mercaptoethanol [36]). The solution was precipitated by addition of
150 ml of 50% (w/v) trichloroacetic acid for 10 min on ice, and the
precipitate was harvested by centrifugation (10 min, 14.000 rpm,
4uC). After complete removal of supernatants, the pellets were dried
briefly at room temperature and resuspended in 100 ml of sample
buffer (for composition, see [36]). Samples were incubated for
10 min at 65uC and spun down briefly. 0.5 OD600 equivalents were
then loaded onto 7% SDS gels and separated at 150 V. After semi-
dry electroblotting (Biorad) onto nitrocellulose, the membrane was
blocked for 30 min in TBS-T with 5% non-fat dried milk and then
probed with a 1:2500 dilution of the polyclonal rabbit antiserum
K168 directed against human BSEP [28].
For S. cerevisiae,2O D 600 equivalents of cells were taken and
processed. the pellets were resuspended in 80 ml of sample buffer,
and 20 ml (0.5 OD600 equivalents) were resolved on a 7% SDS gel.
The E. coli-free site-directed mutagenesis (DREAM)
For introduction of the missense, BstBI mutation into BSEP
constructs, the mutagenesis primer pair BSEP-BstBImut-S1/-S2
was used. Cycling conditions were as in the classic SDM protocol,
with 18 cycles to avoid PCR-induced errors, and with the
annealing temperature strictly being kept at 60uC to ensure the
generation of ds-ended mutagenesis product (also see Figure S1).
Reactions were set up with the Phusion H DNA polymerase, as this
proofreading enzyme has a low error rate practically identical to
the enzyme used in the Stratagene SDM kits (according to the
manufacturers’ datasheets: 4.4610
27 for Phusion H High Fidelity
Polymerase, 4.3610
27 for PfuUltra H HF Polymerase). Extension
time was 1 min per kb to allow for complete extension. The
recommended elongation time for Phusion polymerase is 15–
30 seconds per kbp, and an extended incubation at the elongation
step was found to be important for a successful exponential
product generation, probably because it ensures the quantitative
integrity of the ends that serve as priming sites in subsequent
cycles. 10 ng of template was used, and the reaction was initiated
after heating the reaction to 98uC (hot start) with 0.5 ml of Phusion
polymerase. The reaction was precipitated with sodium acetate
and ethanol, and directly resuspended in 20 ml( = 4O D 600
equivalents) of fresh competent yeast cells in LATE buffer. This
assures an optimal ratio of mutagenesis product to yeast cells. The
transformation was carried out as described above by addition of
120 ml PLATE buffer (40% (v/v) PEG 4000, 0.1 M lithium
acetate, 10 mM Tris-HCl pH 8, 1 mM EDTA).
Yeast colony PCR
Freshly growing transformant colonies were picked and
restreaked onto selective agar plates. The remaining of the
material was treated with Zymolyase for 45 min at 37uCi n5 0ml
reaction volume (0.1 M sodium phosphate buffer pH 7.4, 2 mM
DTT, and 5–10 mg/ml of Zymolyase T-100 (ICN)). After heating
the reactions to 95uC for 10 min, the material was frozen at
220uC for 10 min and thawed again. 5 ml of this were used as
template for colony PCR (30 ml reaction in Phusion HF buffer:
2 mM final conc. of MgCl2, 20 pmol/primer, 200 mM dNTPs, 1.5
units Phusion H DNA polymerase). 10 ml of the reaction was
directly digested with BstBI (15 ml reaction, 8 units restriction
enzyme) for 1 h at 37uC and then resolved on a 1% agarose gel.
Plasmid recovery from yeast
Small- (5–10 ml for E. coli transformation) or large-scale (0.5–1 l
for obtaining preparative plasmid amounts) overnight yeast liquid
yeast cultures were harvested, washed in cold water once, and then
resuspended in Zymolyase incubation buffer (see above, with 1.2 M
sorbitol). The yeast cell wall was digested for 30 min at 37uC, cells
were then lysed by alkaline lysis as described in [30]. 0.5–1 mlo ft h i s
preparation was used to transform chemically competent E. coli
strain XL1blue. After heat shock, bacteria were shaken for 1 h at
30uC and 200 rpm. This low temperature is crucial to prevent the
loss of unstable construct. After plating out on low salt LB media
containing 50 mg/ml Carbenicillin, plates were incubated at 30uC.
Carbenicillin allows for a tighter and longer lasting selection as it
hydrolyzes much slower than ampicillin. 150 ml low salt LB with
Carbenicillin were then directly inoculated with a single colony and
allowedtogrowfor36to 48 hoursat30uCand200 rpm.Cellswere
harvested and plasmid prepared from these. The plasmids were
sequence-verified.
Transfection of cell lines with wt and BstBI-mutated
BSEP-YFP and immunofluorescence analyses
pEYFP-N1-BSEP was made yeast-compatible as described for
pPIC3.5 by addition of an Ori/Leu PCR product made from
YEpHIS with primer pair OriLeu-pEYFP-AflII-S1/-S2.
HepG2 cells (ATCC, ordering number HB-8065) were cultured
in Dulbecco’s modified Eagle’s medium Nutrimix F12 (DMEM-
F12; Invitrogen), HEK293 cells (ATCC, ordering number CRL-
1573) were cultured in DMEM and MDCK cells were cultured in
MEM with Earle’s Salts, each containing 10% fetal calf serum
(PAA, Coelbe, Germany), in a humidified, 5% CO2-atmosphere at
37uC. The indicated BSEP-YFP plasmid DNA was transfected
using FuGENE H HD (Roche) according to the manufacturer’s
guidelines. For fluorescence microscopy (LSM 510, Zeiss,
Oberkochen, Germany) cells were fixed and permeabilized with
methanol (100%, 4uC, 1 min) and nuclei were stained with
Hoechst 34580 (Invitrogen).
Flow cytometric analysis
HEK293 cells transiently transfected with equimolar amounts of
BSEPwt in pEYFP-N1 (1 mg) and in pEYFP-N1-OriLeu
(1.38 mg), respectively, and untransfected cells were cultured in
12-well culture plates until subconfluence. For flow cytometric
analyses they were washed with ice-cold phosphate buffered
saline (PBS) and incubated with Accutase at 37uC. Cells were
An Entire Yeast-Based Mutagenesis Procedure
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e20562transferred into 1.5 ml tubes, centrifuged for 30 sec at 45006g
and resuspended in FACS buffer (PBS+5% (v/v) FCS+0,1 %
(w/v) NaN3). Cell size, granularity and fluorescence intensities
were measured by a FACSCanto Flow Cytometer (Becton
Dickinson, Heidelberg, Germany) with excitation at 488 nm.
EYFP fluorescence was measured at 530630 nm. Transfected
cells were gated by comparisonw i t ht h ef l u o r e s c e n c eo f
untransfected control cells.
Supporting Information
Figure S1 Maps of the ‘‘yeast-enabled’’ plasmids used
in this study for expression and DREAM mutagenesis of
the unstable BSEP cDNA. A, pPIC3.5-OriLeu-CHISBSEP for
heterologous expression in Pichia pastoris. B, pEYFP-N1-OriLeu-
BSEP for expression in mammalian cell culture. Plasmid features
used for propagation in E. coli, S. cerevisiae, and the organism used
for BSEP expression are indicated in red, green, and blue,
respectively.
(DOC)
Figure S2 A simple modification of the classic site-
directed mutagenesis protocol allows the mutagenesis of
toxic or unstable plasmids without the need for E. coli.
The classic site-directed mutagenesis (left cartoon side) results in
am u t a t e da n dl i n e a rp l a s m id with single-stranded 59-overhangs
formed by the mutagenesis primers. Since the primers are
absolutely complementary to each other, the product of the
SDM reaction exists de facto in a non-covalently closed circular
form that is nick-repaired after transformation into E. coli.T h e
polymerase-involving mutagenesis reaction is, in contrast to
standard PCR, non-exponential: the mutagenesis primers
completely overlap (step 1), so the only primer binding sites
on the generated SDM product would be at its very ends.
These, however, are single-stranded (step 2), and cannot, in the
second cycle, serve to further amplify the product of the first
cycle (step 3). Instead, in each cycle the primers bind to the
original template and generate a linear product with themselves
forming the single-stranded 59-overhangs (step 4). Along with
the use of a proofreading DNA polymerase, this assures a
minimum of PCR-introduced mutations, as only the original
plasmid is copied and thus mutated in each of the 18 reaction
cycles. However, because of the low product yield resulting
from the linear template amplification, it is also necessary to
remove the unmutated template to minimize the chance of
picking wild type clones after transformation. The restriction
enzyme DpnI is generally used to recognize and digest both the
methylated plasmid template and hemimethylated heteroduplex
strands while leaving intact the unmethylated mutagenesis
product. Native yeast DNA, however, is unmethylated. We
solved both the problem of low product yield and false positives
by changing the mutagenesis primer design from a complete to
a partial, 59-overlap of the pair (right cartoon side, step 1). A
shift of primer positions has previously been reported in a
different context [4] and this changes the mutant strand
synthesis reaction into a true exponential PCR reaction,
because with this primer design a product is generated (step
2) that carries binding sites for the primers and can serve as
template in the subsequent reaction cycles (step 3). In classic
S D M ,t h et e m p l a t eh a st oc o m p e t ew ith the oligonucleotides for
priming, because they allow for just as much base pairing as
itself, if the primer-template mismatch due to the mutation is
not taken into account (left cartoon side, step 1). In contrast,
the reduction of the primer complementarity to 20 bases greatly
favors the 30 plus 20 bases annealing to the template in the first
cycle (right cartoon side, step 2). More importantly yet, it still
outcompetes in subsequent cycles, when the primers can anneal
to the plasmid template with 50 bases and to the product
template with 30 bases as compared to the 20 bases of
unproductive primer-primer annealing. While the 10 additional
bases do not drastically favor mutagenesis product priming in
the second cycle, already at the end of this cycle the first
product molecules with double-stranded ends appear, which
subsequently are drastically preferred priming targets offering
t h ef u l l5 0b a s e s .T om a k es u r et h a tt h ee n d so ft h ef i n a l
reaction product are double-stranded, the annealing tempera-
ture is strictly kept at 60uC, which is well above the melting
temperature for a 20-mer and prevents the protection of single-
stranded ends by unproductive primer annealing.
(DOC)
Figure S3 FACS analysis of the unmodified and ‘‘yeast-
enabled’’ mammalian BSEP expression vector pEYFP-
N1-BSEP. The data indicate that while pEYFP-N1-OriLeu is
transfected at a somewhat reduced yet comparable efficiency as
the unmodified construct, while the mean fluorescence is even
slightly higher. Taken together with Figure 3, this clearly shows
that the addition of the Ori/Leu segment to the vector
backbone does not compromise construct performance. The
data shown here is representative for three independent
transfection experiments.
(DOC)
Table S1 PCR primers used in this study.
(DOC)
Table S2 Plasmids used in this study.
(DOC)
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